350 related articles for article (PubMed ID: 30414864)
1. Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: A multicenter, randomized, double-blind, placebo-controlled phase II trial.
Hirschfield GM; Chazouillères O; Drenth JP; Thorburn D; Harrison SA; Landis CS; Mayo MJ; Muir AJ; Trotter JF; Leeming DJ; Karsdal MA; Jaros MJ; Ling L; Kim KH; Rossi SJ; Somaratne RM; DePaoli AM; Beuers U
J Hepatol; 2019 Mar; 70(3):483-493. PubMed ID: 30414864
[TBL] [Abstract][Full Text] [Related]
2. Rosuvastatin improves the FGF19 analogue NGM282-associated lipid changes in patients with non-alcoholic steatohepatitis.
Rinella ME; Trotter JF; Abdelmalek MF; Paredes AH; Connelly MA; Jaros MJ; Ling L; Rossi SJ; DePaoli AM; Harrison SA
J Hepatol; 2019 Apr; 70(4):735-744. PubMed ID: 30529590
[TBL] [Abstract][Full Text] [Related]
3. A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis.
Kowdley KV; Vuppalanchi R; Levy C; Floreani A; Andreone P; LaRusso NF; Shrestha R; Trotter J; Goldberg D; Rushbrook S; Hirschfield GM; Schiano T; Jin Y; Pencek R; MacConell L; Shapiro D; Bowlus CL;
J Hepatol; 2020 Jul; 73(1):94-101. PubMed ID: 32165251
[TBL] [Abstract][Full Text] [Related]
4. NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Harrison SA; Rinella ME; Abdelmalek MF; Trotter JF; Paredes AH; Arnold HL; Kugelmas M; Bashir MR; Jaros MJ; Ling L; Rossi SJ; DePaoli AM; Loomba R
Lancet; 2018 Mar; 391(10126):1174-1185. PubMed ID: 29519502
[TBL] [Abstract][Full Text] [Related]
5. The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS-9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis.
Trauner M; Gulamhusein A; Hameed B; Caldwell S; Shiffman ML; Landis C; Eksteen B; Agarwal K; Muir A; Rushbrook S; Lu X; Xu J; Chuang JC; Billin AN; Li G; Chung C; Subramanian GM; Myers RP; Bowlus CL; Kowdley KV
Hepatology; 2019 Sep; 70(3):788-801. PubMed ID: 30661255
[TBL] [Abstract][Full Text] [Related]
6. norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis.
Fickert P; Hirschfield GM; Denk G; Marschall HU; Altorjay I; Färkkilä M; Schramm C; Spengler U; Chapman R; Bergquist A; Schrumpf E; Nevens F; Trivedi P; Reiter FP; Tornai I; Halilbasic E; Greinwald R; Pröls M; Manns MP; Trauner M;
J Hepatol; 2017 Sep; 67(3):549-558. PubMed ID: 28529147
[TBL] [Abstract][Full Text] [Related]
7. NGM282 for Treatment of Patients With Primary Biliary Cholangitis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial.
Mayo MJ; Wigg AJ; Leggett BA; Arnold H; Thompson AJ; Weltman M; Carey EJ; Muir AJ; Ling L; Rossi SJ; DePaoli AM
Hepatol Commun; 2018 Sep; 2(9):1037-1050. PubMed ID: 30202819
[TBL] [Abstract][Full Text] [Related]
8. Prolonged fibroblast growth factor 19 response in patients with primary sclerosing cholangitis after an oral chenodeoxycholic acid challenge.
Zweers SJ; de Vries EM; Lenicek M; Tolenaars D; de Waart DR; Koelfat KV; Groen AK; Olde Damink SW; Beuers U; Ponsioen C; Jansen PL; Schaap FG
Hepatol Int; 2017 Jan; 11(1):132-140. PubMed ID: 27696157
[TBL] [Abstract][Full Text] [Related]
9. Potent suppression of hydrophobic bile acids by aldafermin, an FGF19 analogue, across metabolic and cholestatic liver diseases.
Sanyal AJ; Ling L; Beuers U; DePaoli AM; Lieu HD; Harrison SA; Hirschfield GM
JHEP Rep; 2021 Jun; 3(3):100255. PubMed ID: 33898959
[TBL] [Abstract][Full Text] [Related]
10. Combination Therapy of All-Trans Retinoic Acid With Ursodeoxycholic Acid in Patients With Primary Sclerosing Cholangitis: A Human Pilot Study.
Assis DN; Abdelghany O; Cai SY; Gossard AA; Eaton JE; Keach JC; Deng Y; Setchell KD; Ciarleglio M; Lindor KD; Boyer JL
J Clin Gastroenterol; 2017 Feb; 51(2):e11-e16. PubMed ID: 27428727
[TBL] [Abstract][Full Text] [Related]
11. NGM282 Improves Liver Fibrosis and Histology in 12 Weeks in Patients With Nonalcoholic Steatohepatitis.
Harrison SA; Rossi SJ; Paredes AH; Trotter JF; Bashir MR; Guy CD; Banerjee R; Jaros MJ; Owers S; Baxter BA; Ling L; DePaoli AM
Hepatology; 2020 Apr; 71(4):1198-1212. PubMed ID: 30805949
[TBL] [Abstract][Full Text] [Related]
12. A nontumorigenic variant of FGF19 treats cholestatic liver diseases.
Luo J; Ko B; Elliott M; Zhou M; Lindhout DA; Phung V; To C; Learned RM; Tian H; DePaoli AM; Ling L
Sci Transl Med; 2014 Jul; 6(247):247ra100. PubMed ID: 25080475
[TBL] [Abstract][Full Text] [Related]
13. Simtuzumab for Primary Sclerosing Cholangitis: Phase 2 Study Results With Insights on the Natural History of the Disease.
Muir AJ; Levy C; Janssen HLA; Montano-Loza AJ; Shiffman ML; Caldwell S; Luketic V; Ding D; Jia C; McColgan BJ; McHutchison JG; Mani Subramanian G; Myers RP; Manns M; Chapman R; Afdhal NH; Goodman Z; Eksteen B; Bowlus CL;
Hepatology; 2019 Feb; 69(2):684-698. PubMed ID: 30153359
[TBL] [Abstract][Full Text] [Related]
14. A placebo-controlled randomised trial of budesonide for PBC following an insufficient response to UDCA.
Hirschfield GM; Beuers U; Kupcinskas L; Ott P; Bergquist A; Färkkilä M; Manns MP; Parés A; Spengler U; Stiess M; Greinwald R; Pröls M; Wendum D; Drebber U; Poupon R
J Hepatol; 2021 Feb; 74(2):321-329. PubMed ID: 32950590
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of curcumin in primary sclerosing cholangitis: an open label pilot study.
Eaton JE; Nelson KM; Gossard AA; Carey EJ; Tabibian JH; Lindor KD; LaRusso NF
Scand J Gastroenterol; 2019 May; 54(5):633-639. PubMed ID: 31131678
[No Abstract] [Full Text] [Related]
16. Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis.
Harrison SA; Neff G; Guy CD; Bashir MR; Paredes AH; Frias JP; Younes Z; Trotter JF; Gunn NT; Moussa SE; Kohli A; Nelson K; Gottwald M; Chang WCG; Yan AZ; DePaoli AM; Ling L; Lieu HD
Gastroenterology; 2021 Jan; 160(1):219-231.e1. PubMed ID: 32781086
[TBL] [Abstract][Full Text] [Related]
17. Safety and Sustained Efficacy of the Farnesoid X Receptor (FXR) Agonist Cilofexor Over a 96-Week Open-label Extension in Patients With PSC.
Trauner M; Bowlus CL; Gulamhusein A; Hameed B; Caldwell SH; Shiffman ML; Landis C; Muir AJ; Billin A; Xu J; Liu X; Lu X; Chung C; Myers RP; Kowdley KV
Clin Gastroenterol Hepatol; 2023 Jun; 21(6):1552-1560.e2. PubMed ID: 35934287
[TBL] [Abstract][Full Text] [Related]
18. Novel serum and bile protein markers predict primary sclerosing cholangitis disease severity and prognosis.
Vesterhus M; Holm A; Hov JR; Nygård S; Schrumpf E; Melum E; Thorbjørnsen LW; Paulsen V; Lundin K; Dale I; Gilja OH; Zweers SJLB; Vatn M; Schaap FG; Jansen PLM; Ueland T; Røsjø H; Moum B; Ponsioen CY; Boberg KM; Färkkilä M; Karlsen TH; Lund-Johansen F
J Hepatol; 2017 Jun; 66(6):1214-1222. PubMed ID: 28161472
[TBL] [Abstract][Full Text] [Related]
19. Effects of NGM282, an FGF19 variant, on colonic transit and bowel function in functional constipation: a randomized phase 2 trial.
Oduyebo I; Camilleri M; Nelson AD; Khemani D; Nord SL; Busciglio I; Burton D; Rhoten D; Ryks M; Carlson P; Donato L; Lueke A; Kim K; Rossi SJ; Zinsmeister AR
Am J Gastroenterol; 2018 May; 113(5):725-734. PubMed ID: 29717197
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Cenicriviroc in Patients With Primary Sclerosing Cholangitis: PERSEUS Study.
Eksteen B; Bowlus CL; Montano-Loza AJ; Lefebvre E; Fischer L; Vig P; Martins EB; Ahmad J; Yimam KK; Pockros PJ; Feld JJ; Minuk G; Levy C
Hepatol Commun; 2021 Mar; 5(3):478-490. PubMed ID: 33681680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
